These 3 Tailwinds Could Make International Stocks Fly for Years. Should You Buy Them?

International stocks are outperforming: iShares Core MSCI Total International Stock ETF (IXUS) is up 29% over 12 months vs. the S&P 500’s 22%, supported by a valuation gap (international P/E ~18 vs. S&P 500 ~26.5). The article argues the “AI premium” is concentrated in U.S. mega-cap tech (top-7 cluster trading near ~28x forward earnings) while international trades at ~14.6x, implying a potential rerating if AI productivity lifts earnings. It also points to China’s regulatory “maturation” via reforms to the QFII regime (two-year plan starting Oct 2025) aimed at greater transparency and stronger investor protections, though political risk remains.

Analysis

The important market mechanism here is not “international is cheap,” which has been true for years, but whether U.S. leadership has become crowded enough that even modest earnings disappointments force marginal capital into alternative exposures. That makes the setup more about positioning and factor rotation than about a clean fundamental re-rating; the first winners are likely broad, liquid vehicles like IXUS rather than idiosyncratic single-country bets.

The second-order effect is that the AI trade may be self-limiting at the index level. If AI-driven earnings growth stays concentrated in a handful of U.S. megacaps, the market is effectively paying a high multiple for narrow breadth, which leaves the rest of the S&P 500 vulnerable to multiple compression if rates stay sticky or growth cools. International baskets do not need to “beat” U.S. AI on earnings; they mainly need the valuation gap to stop widening, which is a lower hurdle and can happen quickly if active managers start de-risking crowded U.S. exposure.

China is the highest-beta expression, but also the least investable on a clean basis. A more transparent QFII/dividend/buyback regime would matter most for capital allocation at the margin, not for outright business fundamentals, so BABA is a plausible beneficiary only if policy follow-through is credible and sustained. The contrarian risk is that the policy improvement story is real but too slow to matter for performance over the next 1-3 months, while geopolitical headlines can still overpower it in a day.

Consensus may be underestimating how much of the international bull case is a relative-value trade rather than a growth trade. If U.S. large-cap tech remains the dominant earnings engine, international still can outperform on multiple expansion alone, but that usually requires a catalyst such as a stronger dollar rollover, softer U.S. earnings revisions, or a broadening in global PMIs. Absent those, the move can easily stall after the first wave of “rotation” buying.

Key Decisions for Investors

• Initiate a small relative-value long IXUS / short QQQ position over 1-3 months as a mean-reversion trade on crowded U.S. leadership; target 5-8% spread compression, but cut if U.S. megacap earnings revisions reaccelerate or QQQ makes a new high on expanding breadth.
• Add BABA as a tactical 6-12 month policy-normalization play only on weakness; the setup is a potential multiple rerating if governance and capital-return disclosures improve, but the thesis is invalidated quickly by renewed regulatory tightening or adverse geopolitical headlines.
• Use NVDA as a hedge against the rotation thesis rather than a short: if AI breadth broadens beyond the mega-cap names, the relative-value long IXUS trade becomes less attractive, so keep size modest and monitor AI capex commentary as the key falsifier.
• If looking for lower-risk participation, prefer IXUS over single-country China exposure for now; broad international rerating has a better probability-weighted profile because it requires only a halt in U.S. multiple expansion, not a full China recovery.
• Set an alert for a 1-2 turn compression in the S&P 500 forward P/E or a 50-100 bps drop in U.S. real yields; that would be the cleaner catalyst to add to IXUS and reduce any short-QQQ hedge.